CAS: 497871-47-3; (1′r,6R,6Ar,7R,13S,14S,16R)-8,14-Dihydroxy-6′,9-Dimethoxy-4,10,23-Trimethyl-19-Oxo-2′,3′,4′,6,7,9′,12,13,14,16-Decahydro-6Ah-Spiro[7,13-Azano-6,16-(Epithiopropanooxymethano)[1,3]Dioxolo[7,8]Isoquinolino[3,2-B][3]Benzazocine-20,1′-Pyrido[3,4-B]Indol]-5-Yl Acetate

上下游产品

[(1R,2R,3R,11S,12R,14R,26R)-12-Cyano-6-Methoxy-7,21,30-Trimethyl-27-Oxo-5-Prop-2-Enoxy-26-(Prop-2-Enoxycarbonylamino)-17,19,28-Trioxa-24-Thia-13,30-Diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]Triaconta-4(9),5,7,15,20,22-Hexaen-22-Yl] Acetate 442663-63-0
Tert-Butyl N-[(2S)-1-[[(1R,2S,10R,12R,13S)-12-Cyano-7,18-Dimethoxy-19-(Methoxymethoxy)-6,17,21-Trimethyl-5,8-Dioxo-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),6,15(20),16,18-Pentaen-10-Yl]Methylamino]-1-Oxopropan-2-Yl]Carbamate 308359-25-3
Tert-Butyl N-[(2S)-1-[[(1R,2S,10R,12R,13S)-12-Cyano-19-Hydroxy-7,18-Dimethoxy-6,17,21-Trimethyl-5,8-Dioxo-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),6,15(20),16,18-Pentaen-10-Yl]Methylamino]-1-Oxopropan-2-Yl]Carbamate 308359-24-2
(2S)-N-[[(1R,2S,10R,12R,13S)-12-Cyano-19-Hydroxy-7,18-Dimethoxy-6,17,21-Trimethyl-5,8-Dioxo-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),6,15(20),16,18-Pentaen-10-Yl]Methyl]-2-(Phenylcarbamoylamino)Propanamide 1350888-46-8
Cyanosafracin B
(2S)-N-[[(1R,2S,10R,12R,13S)-12-Cyano-19-Hydroxy-18-Methoxy-6,17,21-Trimethyl-5,7,8-Tris(Prop-2-Enoxy)-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),5,7,15(20),16,18-Hexaen-10-Yl]Methyl]-2-(Phenylcarbamothioylamino)Propanamide 1350888-92-4
(1R,2S,10R,12R,13S)-19-Hydroxy-10-(Hydroxymethyl)-18-Methoxy-6,17,21-Trimethyl-5,7,8-Tris(Prop-2-Enoxy)-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),5,7,15(20),16,18-Hexaene-12-Carbonitrile 1350889-02-9
(1R,2S,10R,12R,13S)-10-(Hydroxymethyl)-7,18-Dimethoxy-6,17,21-Trimethyl-5,8,19-Tris(Prop-2-Enoxy)-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),5,7,15(20),16,18-Hexaene-12-Carbonitrile 1350888-50-4
(2S)-2-Amino-N-[[(1R,2S,10R,12R,13S)-12-Cyano-19-Hydroxy-18-Methoxy-6,17,21-Trimethyl-5,7,8-Tris(Prop-2-Enoxy)-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),5,7,15(20),16,18-Hexaen-10-Yl]Methyl]Propanamide 1350888-87-7
(1R,2S,10R,12R,13S)-10-(Aminomethyl)-19-Hydroxy-18-Methoxy-6,17,21-Trimethyl-5,7,8-Tris(Prop-2-Enoxy)-11,21-Diazapentacyclo[11.7.1.02,11.04,9.015,20]Henicosa-4(9),5,7,15(20),16,18-Hexaene-12-Carbonitrile 1350888-97-9

[(1R,3R,11S,12R,14R,26R)-12-Cyano-5-Hydroxy-6,6'-Dimethoxy-7,21,30-Trimethyl-27-Oxospiro[17,19,28-Trioxa-24-Thia-13,30-Diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]Triaconta-4(9),5,7,15,20,22-Hexaene-26,1'-2,3,4,9-Tetrahydropyrido[3,4-B]Indole]-22-Yl] Acetate 反应生成 鲁贝替定
参考文献: Antitumoral Analogs[fr] Analogues Antitumoraux
标题: Antitumoral Analogs[fr] Analogues Antitumoraux
摘要:本发明涉及通式(i)的ecteinascidin 736的衍生物,其中基团r1,R2,R3,R4和r5各自独立地选自包括h,Oh,Or',Sh,Sr',Sor',So2R',C(=o)r',C(=o)or',No2,Nh2,Nhr',N(r')2,Nhc(o)r',Cn,卤素,=o,取代或未取代的c1-C25烷基,取代或未取代的c2-C18烯基,取代或未取代的c2-C18炔基,取代或未取代的芳基,取代或未取代的杂环的群;其中x是独立选自or',Cn,(=o)或h的群;其中每个r'基团是独立选自包括h,Oh,No2,Nh2,Sh,Cn,卤素,=o,C(=o)h,C(=o)ch3,Co2H,取代或未取代的c1-C25烷基,取代或未取代的c2-C18烯基,取代或未取代的c2-C18炔基,取代或未取代的芳基的群;其中m为0,1或2;其中n为0,1,2,3或4,并用作抗肿瘤剂.

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-2024197726-A1
优先权日:2021-03-03
标 题:Novel tetrahydroisoquinoline alkaloid compound containing macrocycle
发明人：OGURI HIROKI; TANIFUJI RYO
权利人:UNIV TOKYO
摘要:[Problem] To provide: a novel tetrahydroisoquinoline (THIQ) alkaloid compound having a macrocyclic structure; an intermediate of the compound; and a method for producing the compound.[Solution] Provided is a compound represented by formula (I), or a pharmaceutically acceptable salt thereof.The present invention also provides: a method for synthesizing this compound; and an intermediate compound useful in this synthesis.

专利号:CN-117659032-A
优先权日:2022-08-29
标 题 :Intermediates of ascidin derivatives and their synthesis methods